Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677754 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase 2 study of Alzheimers Disease, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
- 20
- Study locations
NCT01677754 is a Phase 2 study of Alzheimers Disease that has completed, run by Hoffmann-La Roche. The registered enrollment target is 542 participants, below the 4,058-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT01677754, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease. Participants who are taking background therapy of acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4 months before screening will be randomized to receive either one of two doses of RO4602522 or placebo for 12 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Memantine
- DRUG Rivastigmine
- DRUG Donepezil
- DRUG RO4602522
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Meridien Research - Brooksville
- Brain Matters Research, Inc. - Delray Beach
- Neurologic Consultants, P.A. - Fort Lauderdale
- Galiz Research, LLC - Hialeah
- Miami Jewish Health Systems - Miami
- Medical Research Group of Central Florida - Orange City
- Compass Research East, LLC - Orlando
- Comprehensive Clinical Development, Inc.- St. Petersburg, FL - St. Petersburg
- Axiom Clinical Research of Florida - Tampa
- Premiere Research Institute - West Palm Beach
California
- Advanced Research Center, Inc.;In-Patient Unit - Anaheim
- Neurology Center of North Orange County - Fullerton
- Torrance Clinical Research - Lomita
- Artemis Institute for Clinical Research, LLC - San Diego
- Sharp Mesa Vista Hospital - San Diego
- San Francisco Clinical Research Center - San Francisco
- Neurological Research Inst - Santa Monica
Connecticut
- Yale University School Of Medicine - New Haven
- Research Center for Clinical Studies, Inc. - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2012-10-24 |
| Est. Completion | 2015-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677754
The ClinicalTrials.gov registry entry for NCT01677754 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 542 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,058-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (87% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01677754 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01677754 about?
NCT01677754 is a clinical study titled "A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy". This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease. Participants who are taking background therapy of acetylcholinesterase inhibitors (AChEI) alon...
What is the current status of trial NCT01677754?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2012-10-24. Estimated completion is 2015-06-12.
What conditions does trial NCT01677754 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01677754?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG), Rivastigmine (DRUG), Donepezil (DRUG), RO4602522 (DRUG).
Who is sponsoring clinical trial NCT01677754?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01677754 being conducted?
This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.